key: cord-1029942-gxpcb25d authors: Voicu, Sebastian; Chousterman, Benjamin G.; Bonnin, Philippe; Deye, Nicolas; Malissin, Isabelle; Gall, Arthur Le; Barthélémy, Romain; Sutterlin, Laetitia; Naim, Giulia; Mrad, Aymen; Pepin-Lehalleur, Adrien; Dorze, Matthieu Le; de Roquetaillade, Charles; Ekhérian, Jean-Michel; Gayat, Etienne; Sidéris, Georgios; Mebazaa, Alexandre; Mégarbane, Bruno title: Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19 date: 2020-11-20 journal: J Infect DOI: 10.1016/j.jinf.2020.11.019 sha: 1f4e6936c78f3b7317f42df8be4060b46a9461c2 doc_id: 1029942 cord_uid: gxpcb25d nan Coronavirus disease-2019 (COVID-19) has been associated with life-threatening thromboembolic complications due to increased inflammation, marked hypercoagulability and endothelial activation. [1] [2] [3] Preventing deep vein thrombosis (DVT) and pulmonary embolism is important, since ~10% of COVID-19-related deaths are caused by pulmonary embolism complicating DVT. 4 Recently, enhanced prophylactic or therapeutic anticoagulation dose regimens have been recommended by experts and adopted in some centres. 5, 6 However, direct comparative studies of the different anticoagulation regimens are lacking. In our intensive care unit (ICU), we established a DVT prevalence of 46% in mechanically ventilated COVID-19 patients on standard prophylactic anticoagulation 7 and subsequently, we increased anticoagulation to reduce thromboembolic complications. We designed this before-after observational exploratory study to evaluate the risk/benefit ratio of increased (IA) versus standard prophylactic anticoagulation (SPA) in mechanically ventilated COVID-19 patients. The study was part of the COVID-ICU and French COVID-19 cohort registries and received approval from the ethics committee of our institution (N°, IDRCB, 2020-A00256-33; CPP, 11-20.20.02.04.68737). We included all consecutive patients admitted for COVID-19-related pneumonia requiring tracheal intubation. We excluded patients on long-term therapeutic anticoagulation before ICU admission. To diagnose DVT, an initial ultrasound was routinely performed during the first week after intubation, and in DVT-free patients, a second ultrasound was performed ~1week later by certified sonographers (SV/PB) according to guidelines. 8 The study was composed of two periods, defined according to the type of anticoagulation received from intubation to the first ultrasound examination. In both groups, if DVT was diagnosed, therapeutic anticoagulation was initiated. Patients admitted from 2020/03/11 to 2020/04/01 (SPA group) received prophylactic anticoagulation with subcutaneous enoxaparin 40mg once daily or unfractionated heparin 15000IU/day if creatinine clearance <15mL/min. Patients admitted from 2020/04/02 to 2020/10/12 (IA group) received either prophylactic double-dose enoxaparin 40mg twice daily or therapeutic anticoagulation with either enoxaparin 1mg/kg twice daily or unfractionated heparin to reach plasma anti-Xa activity of 0.3-0.6IU/mL. Supportive care included optimized mechanical ventilation, vasopressors, sedation and muscular paralysis according to guidelines. Dexamethasone, antiviral and other immunomodulatory drugs were administered according to the physicians in charge. The efficacy endpoint was the prevalence of femoral/popliteal DVT, known to be strongly associated with pulmonary embolism. 9 The efficacy endpoint was also compared between patients treated with double-dose prophylactic enoxaparin (0.4mg twice daily) and patients treated with standard enoxaparin prophylaxis (0.4mg once daily). The safety endpoint was the number of patients with at least one major bleeding (MB) defined according to guidelines, 10 i.e. bleedings causing death, decreasing hemoglobin by ≥2g/dL, requiring transfusion of ≥2 blood units or occurring in a critical organ. Quantitative variables are expressed as medians [25 th -75 th percentiles] and categorical variables as percentages. Parameters were compared between SPA and IA patients using Mann-Whitney and Fisher's exact tests as appropriate. An exploratory generalized multilinear regression model was built to adjust for parameters significantly different between groups. P-values ≤0.05 were considered significant. Based on the 26% prevalence of femoral/popliteal DVT in the SPA group and a presumed reduction to <5% in the IA group, 42 patients/group were required for 95% confidence interval and 80% statistical power. Ninety-three patients were included, 50 in the SPA and 43 in the IA group. Baseline characteristics did not differ significantly between the groups (Table1). The initial ultrasound was performed 2 days [1] [2] [3] [4] post-intubation. Time from ICU admission to the first ultrasound was 4days [2] [3] [4] [5] [6] in the SPA versus 5days [3] [4] [5] [6] [7] [8] Our most important finding is that IA is associated with decreased femoral/popliteal DVT prevalence in comparison with SPA in mechanically ventilated COVID-19 patients. The second important finding is that enoxaparin 0.4 mg twice daily regimen 5 seems effective for DVT prophylaxis compared with standard enoxaparin prophylaxis. To our knowledge, this is the first study comparing SPA with IA strategies and showing a significant reduction in femoral/popliteal DVT using systematic ultrasound screening. Our data suggests that double-dose enoxaparin prophylaxis (40mg twice daily) may have a favorable risk/benefit ratio, worth exploring in further studies. DVT below the popliteal level were not reduced in the IA group, suggesting that at this level, venous stasis and/or endothelial lesion may play a more important role than hypercoagulation. Our study strength is that ultrasound was performed in all patients, avoiding biases related to the absence of systematic screening. Limitations include absence of randomization and small sample size precluding assessment of the effect on mortality. In conclusion, using systematic ultrasound screening, we observed a decrease in femoral/popliteal DVT prevalence while increasing anticoagulation compared to standard prophylaxis in mechanically ventilated COVID-19 patients. The favorable risk/benefit ratio of prophylactic double-dose enoxaparin 40mg twice-daily regimen is worth exploring in future studies. The authors declare no competing interests. All the authors agree to publish. Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection Deep Vein Thrombosis in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: Prevalence, Risk Factors, and Outcome Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring Anticoagulation in Hospitalized Patients with Covid-19 High prevalence of deep vein thrombosis in mechanically ventilated COVID-19 patients Ultrasound for Lower Extremity Deep Venous Thrombosis: Multidisciplinary Recommendations From the Society of Radiologists in Ultrasound Consensus Conference ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients The study, analysis, and manuscript preparation were completed as part of official duties at the university hospital. There was no additional funding.